A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
Public ClinicalTrials.gov record NCT00135395. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIIb, Open -Label, Randomized Multi-center Study Comparing the Antiviral Efficacy, Safety, and Effect on Serum Lipids of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir, in Combination With Two Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTIs) in HIV-1 Infected Subjects Experiencing Their First Virologic Failure While Receiving a NNRTI-containing HAART Regimen.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the anti-HIV efficacy, safety and effect of serum lipids of two boosted protease inhibitor-based HAART regimens (ARV/RTV v. LPV/RTV) in HIV-1 infected subjects who have experienced their first virologic failure while receiving a NNRTI-containing HAART regimen.
Study identification
- NCT ID
- NCT00135395
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 200 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2004 (Type not available)
- Primary completion
- Feb 2006 (Actual)
- Completion
- Feb 2006 (Actual)
- Last update posted
- Feb 5, 2010
2004 – 2006
United States locations
- U.S. sites
- 52
- U.S. states
- 25
- U.S. cities
- 52
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Hobson City | Alabama | — | — |
| Local Institution | Montgomery | Alabama | — | — |
| Local Institution | Phoenix | Arizona | — | — |
| Local Institution | Little Rock | Arkansas | — | — |
| Local Institution | Bakersfield | California | — | — |
| Local Institution | Los Angeles | California | — | — |
| Local Institution | San Francisco | California | — | — |
| Local Institution | San Mateo | California | — | — |
| Local Institution | Tarzana | California | — | — |
| Local Institution | West Hollywood | California | — | — |
| Local Institution | Norwalk | Connecticut | — | — |
| Local Institution | Washington D.C. | District of Columbia | — | — |
| Local Institution | Atlantis | Florida | — | — |
| Local Institution | Fort Lauderdale | Florida | — | — |
| Local Institution | Jacksonville | Florida | — | — |
| Local Institution | Miami | Florida | — | — |
| Local Institution | Miami Beach | Florida | — | — |
| Local Institution | North Miami | Florida | — | — |
| Local Institution | Orlando | Florida | — | — |
| Local Institution | Plantation | Florida | — | — |
| Local Institution | Safety Harbor | Florida | — | — |
| Local Institution | Tampa | Florida | — | — |
| Local Institution | Atlanta | Georgia | — | — |
| Local Institution | Decatur | Georgia | — | — |
| Local Institution | Chicago | Illinois | — | — |
| Local Institution | Indianapolis | Indiana | — | — |
| Local Institution | Louisville | Kentucky | — | — |
| Local Institution | New Orleans | Louisiana | — | — |
| Local Institution | Boston | Massachusetts | — | — |
| Local Institution | Springfield | Massachusetts | — | — |
| Local Institution | Berkley | Michigan | — | — |
| Local Institution | Jackson | Mississippi | — | — |
| Local Institution | St Louis | Missouri | — | — |
| Local Institution | Las Vegas | Nevada | — | — |
| Local Institution | East Orange | New Jersey | — | — |
| Local Institution | Hillsborough | New Jersey | — | — |
| Local Institution | Jersey City | New Jersey | — | — |
| Local Institution | Brooklyn | New York | — | — |
| Local Institution | Mount Vernon | New York | — | — |
| Local Institution | New York | New York | — | — |
| Local Institution | Valhalla | New York | — | — |
| Local Institution | Greenville | North Carolina | — | — |
| Local Institution | Huntersville | North Carolina | — | — |
| Local Institution | Winston-Salem | North Carolina | — | — |
| Local Institution | Oklahoma City | Oklahoma | — | — |
| Local Institution | Philadelphia | Pennsylvania | — | — |
| Local Institution | Columbia | South Carolina | — | — |
| Local Institution | Dallas | Texas | — | — |
| Local Institution | Galveston | Texas | — | — |
| Local Institution | Harlingen | Texas | — | — |
| Local Institution | Houston | Texas | — | — |
| Local Institution | Hampton | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00135395, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 5, 2010 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00135395 live on ClinicalTrials.gov.